Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
Open accessAbstract
// Pei-Yu Huang 1, 2, * , Shan-Shan Guo 1, 2, * , Yu Zhang 1, 3, * , Jia-Bin Lu 1, 3 , Qiu-Yan Chen 1, 2 , Lin-Quan Tang 1, 2 , Lu Zhang 1, 2 , Li-Ting Liu 1, 2 , Li Zhang 1, 4 , Hai-Qiang Mai 1, 2 1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China 2 Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China 3 Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China 4 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China * These authors contributed equally to this work Correspondence to: Li Zhang, e-mail: zhangli@sysucc.org.cn Hai-Qiang Mai, e-mail: maihq@sysucc.org.cn Keywords: CTLA-4, CD28, nasopharyngeal carcinoma, immunohistochemistry, prognostic factor Received: July 05, 2015 Accepted: January 26, 2016 Published: February 16, 2016 ABSTRACT The expression levels of CTLA-4 and CD28 were analyzed in 191 nasopharyngeal carcinoma (NPC) patients diagnosed and treated at our hospital between January 2010 and November 2011. The 3-year overall survival (OS) rate (91.4% vs. 81.2%, p = 0.043), failure-free survival (FFS) rate (82.8% vs. 68.0%, p = 0.009) and distant failure-free survival (D-FFS) rate (85.8% vs. 72.3%, p = 0.006) in the low tumor CTLA-4 expression group was higher than in the high tumor CTLA-4 group. There were no differences between the locoregional failure-free survival (LR-FFS) rates in the high and low tumor CTLA-4 expression groups. Moreover, no differences in the OS, FFS, D-FFS, or LR-FFS were observed between the groups with high and low lymphocyte CTLA-4 levels, high and low tumor CD28 levels, or high and low lymphocyte CD28 levels. Cox regression analysis confirmed the prognostic value of tumor CTLA-4 expression, particularly for D-FFS, in NPC patients ( p = 0.044). NPC patients with high tumor CTLA-4 expression had a poorer prognosis than those with low expression.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CTLA-4 may be expressed in tumor lesions on infiltrating Tregs, exhausted conventional T cells, and tumor cells themselves.
“CTLA-4 may be expressed in tumor lesions on infiltrating Tregs or exhausted conventional T cells as well as tumor cells themselves (53, 54).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 22,207 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works
Krummel, M. F., & Allison, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2533 · Cited by 923 · see citing works
Role of the CD28 receptor in T-cell activation
June, C. H., Ledbetter, J. A., Linsley, P. S., & Thompson, C. B. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90085-n · Cited by 674 · see citing works
BAUJAT, B., Audry, H., Bourhis, J., Chan, A. T. �., Onat, H., Chua, D. T. T., Kwong, D. L. �., Al‐Sarraf, M., Chi, K.-H., Hareyama, M., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.037 · Cited by 629 · see citing works
Peng, G., Wang, T., Yang, K., et al. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.08.013 · Cited by 628 · see citing works
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner-Weinzierl, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419 · see citing works
Langendijk, J. A., Leemans, C. R., Buter, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.074 · Cited by 410 · see citing works
At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 349 · see citing works
Epstein-Barr virus and nasopharyngeal carcinoma
Young, L. S., & Dawson, W. O. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10197 · Cited by 296 · see citing works
Kim, J. W., Nam, K. H., Ahn, S.-H., Park, D. J., Kim, H., Kim, S. H., Chang, H. K., Lee, J., Kim, Y. J., Lee, H. S., et al. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0440-5 · Cited by 249 · see citing works
Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription
Staal, F. J. T., Meeldijk, J., Moerer, P., Jay, P., van de Weerdt, B. C. M., Vainio, S. J., Nolan, G. P., & Clevers, H. C. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200101)31:1 · Cited by 200 · see citing works
CD28/CTLA-4 and CD80/CD86 families
Slavik, J. M., Hutchcroft, J. E., & Bierer, B. E. (1999) · Immunologic Research · doi:10.1007/bf02786473 · Cited by 196 · see citing works
Epstein–Barr Virus and Nasopharyngeal Carcinoma
Zhou, X., Xiao, X., Chen, F., et al. (2014) · doi:10.1002/9781118826621.ch14 · Cited by 141 · see citing works
Epstein-Barr virus and nasopharyngeal carcinoma.
Raab‐Traub, N. (1992) · PubMed · Cited by 133 · see citing works
Salvi, S., Fontana, V., Boccardo, S., Merlo, D. F., Margallo, E., Laurent, S., Morabito, A., Rijavec, E., Dal Bello, M. G., Mora, M., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1211-y · Cited by 133 · see citing works
Pistillo, M. P. (2002) · Blood · doi:10.1182/blood-2002-06-1668 · Cited by 127 · see citing works
CD28, a marker associated with tumoral expansion in multiple myeloma.
Robillard, N., Jégo, G., Pellat‐Deceunynck, C., et al. (1998) · PubMed · Cited by 106 · see citing works
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Mao, H., Zhang, L., Yang, Y., Zuo, W., Bi, Y., Gao, W., Deng, B., Sun, J., Shao, Q., & Qu, X. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793605811 · Cited by 97 · see citing works
Self-citationZeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia.
Rossi, E., Matutes, E., Morilla, R. M., Owusu-Ankomah, K. A., Am, H., & Catovsky, D. (1996) · PubMed · Cited by 94 · see citing works
Nair, J. R., Carlson, L. M., Koorella, C., Rozanski, C. H., Byrne, G. E., Bergsagel, P. L., Shaughnessy, J. P., Boise, L., Chanan-Khan, A. A., & Lee, K. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100016 · Cited by 89 · see citing works
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
Schneider, H., & Rudd, C. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00619 · Cited by 62 · see citing works
Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
Chan, K. C. A. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10192 · Cited by 57 · see citing works
Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia
Mittal, A. K., Chaturvedi, N. K., Rohlfsen, R. A., Gupta, P., Joshi, A. D., Hegde, G. V., Bociek, R. G., & Joshi, S. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070352 · Cited by 50 · see citing works
Immunosuppression through biockade of CD28:B7-mediated costimulatory signals
Judge, T. A., Tang, A., & Turka, L. A. (1996) · Immunologic Research · doi:10.1007/bf02918283 · Cited by 33 · see citing works
Xiao, M., Qi, F., CHEN, X.-X., et al. (2009) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2009.00888.x · Cited by 23 · see citing works
Impaired Expression of CD28 on T Cells in Hairy Cell Leukemia
van de Corput, L., Falkenburg, J. H. F., Kester, M. G. D., Willemze, R., & Kluin‐Nelemans, H. C. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4794 · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works
- Authors
- Huang, P.-Y., Guo, S.-S., Zhang, Y., Lu, J.-B., Chen, Q.-Y., Tang, L.-Q., Zhang, L., Liu, L.-T., Zhang, L., & Mai, H.-Q.
- Affiliations
- Sun Yat-sen University (CN)
- Corresponding author
- Huang, Pei-Yu
- Guo, Shan-Shan
- Zhang, Yu
- ORCID
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-16
- Volume
- 7
- Issue
- 11
- Pages
- 13060-13068
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC4914341
- OpenAlex
- W2286633367
- Cited by
- 96
- References
- 32
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 12 · 2020: 15 · 2019: 9 · 2018: 11 · 2017: 5 · 2016: 2
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81425018, 2014TX01R145, 2015010, No. 81425018, 81072226, 201315, 2012AA02A501, 81201629, 2014A)
- Sun Yat-sen University
- China Scholarship Council
- Chinese Society of Clinical Oncology
- Wu Jieping Medical Foundation (320.6750)
- Fundamental Research Funds for the Central Universities (201315)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CTLA-4, CD28, nasopharyngeal carcinoma, tumor immune checkpoint, prognostic factors, overall survival, failure-free survival, distant metastasis, locoregional recurrence, tumor-infiltrating lymphocytes, regulatory T cells, T cell exhaustion, T cell proliferation, T cell apoptosis, T cell activation, T cell differentiation
- MeSH terms
- Nasopharyngeal Carcinoma, Adult, Aged, Carcinoma, Female, Humans, Male, Middle Aged, Nasopharyngeal Neoplasms, Prognosis, Biomarkers, Tumor, Survival Rate, CD28 Antigens, Young Adult, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
